Role of cardiovascular magnetic resonance in the guidelines of the European Society of Cardiology

Knobelsdorff‐Brenkenhoff, Florian von; Schulz‐Menger, Jeanette

doi:10.1186/s12968-016-0225-6

Cited by 146 publications

(98 citation statements)

References 54 publications

(79 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Instead, T 2 has been reported to be elevated in HCM [108] related to presence of inflammation and edema. A T 2 increase would also result in increased T 2 * as seen from Equation (1). Further to this, reduced myocardial perfusion and ischemia are common in HCM [109], effectively reducing the tissue blood volume fraction resulting in a T 2 * increase as suggested by Equation (5).…”

Section: Myocardial T 2 * Mapping In Patients With Cardiovascular Dismentioning

confidence: 94%

“…Thanks to its soft tissue contrast and versatility, cardiovascular magnetic resonance imaging (CMR) has become a vital clinical tool for diagnosis and for guiding therapy of cardiac diseases [1,2]. CMR can provide morphologic and functional information as well as insights into microstructural changes of the heart muscle [2].…”

Section: T 2 * Sensitized Cardiovascular Magnetic Resonancementioning

confidence: 99%

See 1 more Smart Citation

Myocardial T2* Mapping with Ultrahigh Field Magnetic Resonance: Physics and Frontier Applications

Huelnhagen

Paul

et al. 2017

Front. Phys.

View full text Add to dashboard Cite

Cardiovascular magnetic resonance imaging (CMR) has become an indispensable clinical tool for the assessment of morphology, function and structure of the heart muscle. By exploiting quantification of the effective transverse relaxation time (T 2 * ) CMR also affords myocardial tissue characterization and probing of cardiac physiology, both being in the focus of ongoing research. These developments are fueled by the move to ultrahigh magnetic field strengths, which permits enhanced sensitivity and spatial resolution that help to overcome limitations of current clinical MR systems with the goal to contribute to a better understanding of myocardial (patho)physiology in vivo. In this context, the aim of this report is to introduce myocardial T 2 * mapping at ultrahigh magnetic fields as a promising technique to non-invasively assess myocardial (patho)physiology. For this purpose the basic principles of T 2 * assessment, the biophysical mechanisms determining T 2 * and (pre)clinical applications of myocardial T 2 * mapping are presented.Technological challenges and solutions for T 2 * sensitized CMR at ultrahigh magnetic field strengths are discussed followed by a review of acquisition techniques and post-processing approaches. Preliminary results derived from myocardial T 2 * mapping in healthy subjects and cardiac patients at 7.0 T are presented. A concluding section discusses remaining questions and challenges and provides an outlook on future developments and potential clinical applications.

show abstract

Section: Myocardial T 2 * Mapping In Patients With Cardiovascular Dismentioning

confidence: 94%

Section: T 2 * Sensitized Cardiovascular Magnetic Resonancementioning

confidence: 99%

Myocardial T2* Mapping with Ultrahigh Field Magnetic Resonance: Physics and Frontier Applications

Huelnhagen

Paul

et al. 2017

Front. Phys.

View full text Add to dashboard Cite

show abstract

“…Cardiac magnetic resonance imaging (cMRI) has emerged to a standard imaging modality for the diagnosis of heart failure related to coronary artery disease, cardiomyopathies, or myocarditis as well as for cardiac tissue characterization [1–3]. cMRI allows accurate assessment of cardiac function, perfusion, and vitality under resting and stress-induced circumstances due to its higher three-dimensional resolution [4].…”

Section: Introductionmentioning

confidence: 99%

Galectin-3 Reflects Mitral Annular Plane Systolic Excursion Being Assessed by Cardiovascular Magnetic Resonance Imaging

et al. 2016

View full text Add to dashboard Cite

Background. This study investigates whether serum levels of galectin-3 may reflect impaired mitral annular plane systolic excursion (MAPSE) in patients undergoing cardiac magnetic resonance imaging (cMRI). Methods. Patients undergoing cMRI during routine clinical care were included prospectively within an all-comers design. Blood samples for biomarker measurements were collected within 24 hours following cMRI. Statistical analyses were performed in all patients and in three subgroups according to MAPSE (MAPSE I: ≥11 mm, MAPSE II: ≥8 mm–<11 mm, and MAPSE III: <8 mm). Patients with right ventricular dysfunction (<50%) were excluded. Results. 84 patients were included in the study. Median LVEF was 59% (IQR 51–64%). Galectin-3 correlated significantly with NT-proBNP (r = 0.42, p = 0.0001). Galectin-3 increased significantly according to the different stages of impaired MAPSE (p = 0.006) and was able to discriminate both patients with impaired MAPSE <11 mm (area under the curve (AUC) = 0.645, p = 0.024) and <8 mm (AUC = 0.733, p = 0.003). Combining galectin-3 with NT-proBNP improved discrimination of MAPSE <8 mm (AUC 0.803, p = 0.0001). In multivariable logistic regression models galectin-3 was still associated with impaired MAPSE (MAPSE < 11 mm: odds ratio (OR) = 3.53, p = 0.018; MAPSE < 8 mm: OR = 3.18, p = 0.06). Conclusions. Galectin-3 reflects MAPSE being assessed by cardiac MRI.

show abstract

“…16 Moreover, cardiac MRI permits modeling of the left ventricle free of geometric assumptions, without the physical limitations of ultrasound imaging, and with no ionizing radiation to the patient. 17 These observations have led cardiac MRI to become the reference standard for in vivo determination of LV mass 18,19 with additional robust data supporting its larger clinical use. 20 As indicated by the authors however, cardiac MRI, although the reference standard for LV mass measurement, has certain methodological limitations.…”

mentioning

confidence: 99%

Assessment of left ventricular mass by SPECT MPI

Packard

Maddahi

2019

Journal of Nuclear Cardiology

View full text Add to dashboard Cite

A. Gimelli, R. Liga et al. report on left ventricular (LV) mass determination using two commercially available softwares that they applied to cadmium-zinc-telluride (CZT) single-photon emission computed tomography (SPECT) myocardial perfusion imaging (MPI), and compared results to cardiac magnetic resonance imaging (MRI) which was the reference standard. 1 For their study, they retrospectively identified n = 25 patients who underwent MPI with gated 99m Tc-tetrofosmin acquired on a CZT camera and had a cardiac MRI within 12 ± 3 weeks. To put the authors' work on LV mass determination in perspective, we will address the importance, accepted methods, and nuclear imaging approaches to LV mass measurement.A common cardiac adaptive mechanism in the setting of hemodynamic overload is the compensatory increase in LV mass, as explained by the Law of LaPlace in whichwhere s is the ventricular wall stress, P is the ventricular pressure, r is the ventricular radius, and T is the ventricular wall thickness. 2 However, this compensatory increase in ventricular wall thickness is detrimental on the long run, as demonstrated by multiple clinical studies. Indeed, an increase in LV wall thickness or mass, typically due to left ventricular hypertrophy (LVH), predicts an increased risk of cardiovascular morbidity and mortality as determined in the Framingham Heart Study, even after adjustment for major risk factors. 3 Moreover, the severity of LVH is an independent predictor of death and coronary revascularization. 4 These early observations have been confirmed by more contemporary data where LV mass and LVH were found to be predictive of the need for future revascularization, 5 and of the occurrence of myocardial infarction and cardiac death 6 in patients with or without stress-inducible ischemia 7 or in the setting of asymptomatic aortic stenosis. 8 In patients with a previous myocardial infarction, prognosis is related to the percentage of viable LV mass, and LV mass measurement can assess the development of compensatory focal LVH. 9 Quantification of LV mass is also useful in the evaluation and management of patients with valvular heart disease and hypertrophic cardiomyopathy. Further, LV mass has been demonstrated to predict the incidence of congestive heart failure in the Multi-Ethnic Study of Atherosclerosis. 10 In addition, assessment of LV mass can be used to monitor response to therapies such as weight reduction 11 or kidney transplantation. 12

show abstract

Role of cardiovascular magnetic resonance in the guidelines of the European Society of Cardiology

Cited by 146 publications

References 54 publications

Myocardial T2* Mapping with Ultrahigh Field Magnetic Resonance: Physics and Frontier Applications

Myocardial T2* Mapping with Ultrahigh Field Magnetic Resonance: Physics and Frontier Applications

Galectin-3 Reflects Mitral Annular Plane Systolic Excursion Being Assessed by Cardiovascular Magnetic Resonance Imaging

Assessment of left ventricular mass by SPECT MPI

Contact Info

Product

Resources

About